Trial Profile
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy; Sturge-Weber syndrome
- Focus Expanded access; Therapeutic Use
- 08 Feb 2022 Status changed from active, no longer recruiting to completed.
- 15 Apr 2020 Planned End Date changed from 1 Jun 2019 to 1 Apr 2021.
- 28 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.